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Abstract 
Background: Mutations in the POLE gene result in an ultra-hypermutated phenotype in colorectal cancer (CRC); 
however, the molecular characterisation of epigenetic alterations remains unclear. We examined the genetic and 
epigenetic profiles of POLE-mutant CRC to elucidate the clinicopathological features of the associated genetic and 
epigenetic alterations.
Results: Tumour tissues (1,013) obtained from a cohort of patients with CRC were analysed to determine associa-
tions between the proofreading domain mutations of POLE with various clinicopathological variables, microsatel-
lite instability (MSI) status, BRAF and KRAS mutations, and the methylation status of key regions of MLH1, MGMT, and 
SFRP2 promoters by calculating the methylation scores (range 0–6). Only four cases (0.4%) exhibited pathogenic POLE 
hotspot mutations (two p.P286R [c.857C > G], one p.V411L [c.1231G > C], and p.S459F [c.1376C > T] each), which were 
mutually exclusive to BRAF and KRAS mutations and MSI. CRC patients were divided into four subgroups: patients with 
POLE mutations (POLE, 0.4%, n = 4), patients with both MSI and extensive methylation in MLH1 (MSI-M, 2.9%, n = 29), 
patients with MSI but no extensive methylation in MLH1 (MSI-U, 3.6%, n = 36), and patients without MSI (non-MSI, 
93.2%, n = 944). The POLE group was younger at diagnosis (median 52 years, P < 0.0001), with frequent right-sided 
tumour localisation (frequency of tumours located in the right colon was 100%, 93.1%, 36.1%, and 29.9% in POLE, MSI-
M, MSI-U, and non-MSI, respectively; P < 0.0001), and was diagnosed at an earlier stage (frequency of stages I–II was 
100%, 72.4%, 77.8%, and 46.6% in POLE, MSI-M, MSI-U, and non-MSI, respectively, P < 0.0001). The mean methylation 
score in POLE was not different from that in MSI-U and non-MSI, but the methylation signature was distinct from that 
of the other subgroups. Additionally, although the examined number of POLE-mutant tumours was small, the number 
of CD8-positive cells increased in tumours with partial methylation in the MLH1 gene.
Conclusions: CRC patients with POLE proofreading mutations are rare. Such mutations are observed in younger 
individuals, and tumours are primarily located in the right colon. Diagnosis occurs at an earlier stage, and distinct 
epigenetic alterations may be associated with CD8 cell infiltration.
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Background
Most colorectal cancers (CRCs) occur sporadically and 
progress through sequential accumulation of multi-
ple genetic and epigenetic alterations by influencing 
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the expression and behaviour of genes that regulate 
cell growth and differentiation [1–3]. Several crucial 
gene defects in sporadic CRC have been identified, and 
specific molecular phenotypes have been described, 
including chromosomal instability (CIN), microsatellite 
instability (MSI), and the CpG island methylator phe-
notype (CIMP) [1, 3–5]. Although somatic mutations in 
the POLE gene are found in 3–7% of CRCs, mutations 
within the proofreading (exonuclease) domain of POLE 
are present in only 1–2% of CRCs [6–9]. The proofread-
ing potential of POLE is essential for ensuring replication 
fidelity, and its disruption by the pathogenic heterozy-
gous mutations found in cancers leads to an ultra-hyper-
mutated phenotype of tumours, with the highest burden 
of single-nucleotide variants among human cancers 
[6, 10, 11]. Analogous to CRC, patients with endome-
trial cancers harbouring pathogenic POLE exonuclease 
domain mutations have excellent prognosis [6, 7, 10, 12], 
possibly because such an extreme hypermutation event 
causes the enrichment of antigenic neoepitopes, which in 
turn stimulates a potent cytotoxic T-cell response in can-
cer cells [9, 13, 14].
To date, several pivotal studies have characterised 
POLE-mutant CRCs with their corresponding MSI sta-
tus, genetic mutations, tumour lymphocyte infiltration, 
and clinicopathological findings, including clinical out-
comes [6–8, 15]. However, to the best of our knowledge, 
no study has thus far characterised POLE-mutant CRCs 
in the context of epigenetic alterations. The present study 
aimed to evaluate the epigenetic profiles of POLE-mutant 
CRC and elucidate the clinicopathological features asso-
ciated with key genetic and epigenetic alterations in this 
malignancy.
Results
Detection of pathogenic somatic POLE mutations
Of the 1,052 CRC patients, 17 had resected synchro-
nous multiple cancers (one patient had three synchro-
nous tumours and 16 patients had double synchronous 
tumours). Therefore, a total of 1,070 CRC tissues were 
analysed for POLE mutations. None of the patients with 
synchronous multiple cancers displayed POLE mutations 
in their cancer tissues; thus, patients with synchronous 
multiple cancers were analysed by the most advanced 
tumour lesion for further molecular studies (Fig. 1). Path-
ogenic proofreading POLE mutations were detected in 
four CRCs as recurrent variants and are known to cause 
an ultra-mutator phenotype and characteristic muta-
tion spectrum (NM_006231.3: two cases were p.P286R 
[c.857C > G], one was p.V411L [c.1231G > C], and one was 
p.S459F [c.1376C > T], Fig. 2). Regarding germline muta-
tions, the DNA of four patients was sequenced to deter-
mine whether the POLE mutations existed in the DNA 
extracted from their corresponding normal mucosa; 
however, no germline mutations were present.
Evaluation of MSI status
The MSI status of the 1,052 CRC tissues was evaluated. 
None of the four tumours harbouring pathogenic POLE 
mutations displayed MSI features in the four mononu-
cleotide repeat markers [12, 16]. Among the remain-
ing 1,048 CRCs, 6.4% (67/1,048) displayed MSI features, 
while 93.3% (981/1,048) did not exhibit any MSI features 
and were deemed microsatellite stable (non-MSI) (Fig. 1).
Immunohistochemical (IHC) analysis of MMR expression 
in CRCs with MSI
The expression status of the four DNA mismatch repair 
(MMR) proteins (MLH1, MSH2, PMS2, and MSH6) 
was confirmed in all 67 MSI CRC tissues. By IHC anal-
ysis, 11.9% (8/67) were classified as MMR-proficient 
(pMMR), and the remaining 86.8% of MSI CRCs (59/67) 
were confirmed to be MMR-deficient (dMMR). Of the 
59 dMMR tumours, 79.7% (47/59) exhibited both MLH1 
and PMS2 deficiency (dMLH1), 15.3% (9/59) exhibited 
both MSH2 and MSH6-deficiency (dMSH2), 5.1% (3/59) 
exhibited MSH6-deficiency alone (dMSH6), and none 
of the tumours displayed PMS2-deficiency on their own 
(dPMS2). The precise status of IHC staining and MSI 
markers in MSI tumours is shown in Additional file  1: 
Table 1.
Classification of four CRC subtypes according to POLE 
mutations, MSI, and methylation status in the MLH1 
promoter region
Sporadic MSI tumours are primarily caused by inacti-
vation of the MLH1 gene, which has a large CpG island 
within its promoter region that divides it into at least two 
discrete regions of methylation (the AB and C regions in 
this study, Fig.  3a) [17–20]. Inactivation of MLH1 was 
observed when CpG methylation spread through the AB 
to the C region.
In this cohort, no methylation in the AB or C 
region (unmethylated) was observed in 50.0% (2/4) 
of POLE-mutant CRCs, 38.5% (25/65) of MSI CRCs, 
and 85.1% (803/944) of non-MSI CRCs. Partial meth-
ylation in MLH1 (i.e. affecting the AB region only) was 
observed in 50.0% (2/4) of POLE-mutant CRCs, 16.9% 
(11/65) of MSI CRCs, and 14.9% (141/944) of non-
MSI CRCs. Extensive methylation (i.e. affecting both 
the AB and C regions) was observed in 44.6% (29/65) 
of MSI CRCs (P < 0.0001, Fig.  3b) and 64.4% (29/45) 
of dMLH1 tumours, which were suspected to be spo-
radic MSI tumours. In contrast, no extensive methyla-
tion was observed in either dMSH2 or dMSH6 cancers, 
including in patients with Lynch syndrome (Fig.  3c). 
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Therefore, in this study, we classified MSI tumours 
according to their methylation status in the MLH1 pro-
moter; 2.9% (29/1,013) tumours with extensive MLH1 
methylation were categorised as MSI with MLH1 meth-
ylation (MSI-M) and 3.6% (36/1,013) tumours without 
extensive MLH1 methylation as MSI with unmethyl-
ated MLH1 (MSI-U).
Finally, we classified 1,013 CRC patients into four 
subgroups: non-MSI CRC patients with POLE muta-
tions (POLE group, 0.4%, n = 4), MSI CRC patients 






































Patients with synchronous multiple cancers (N=17)
Patients with single primary cancer (N=1,035)
None of the paents with synchronous mulple cancers 
displayed POLE mutaons in their cancer ssues*
Fig. 1 The STROBE diagram of the colorectal cancer patient cohort. *Patients with synchronous multiple cancers based on the most advanced 
tumour lesion were subsequently confirmed pathologically for further molecular studies
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with extensive MLH1 methylation (MSI-M group, 2.9%, 
n = 29), MSI CRC patients with unmethylated MLH1 
(MSI-U group, 3.6%, N = 36), and non-MSI CRC patients 
(non-MSI group, 93.2%, n = 944, Fig. 3d).
Clinical and genetic features of CRC patients with POLE 
mutations
Table 1 illustrates in detail associations between the four 
CRC subgroups and their clinical and genetic features. 
We observed that a significant proportion of tumours 
classified within the POLE group occurred in younger 
patients with a mean age of 52.5  years. Additionally, all 
POLE (4/4) and 93.1% (27/29) of MSI-M were proximally 
located, in contrast to 36.1% (13/36) of MSI-U and 29.9% 
(282/944) of non-MSI. All patients with POLE muta-
tions were diagnosed at an earlier stage (4 out of 4 at 
stages I–II), similar to 72.4% (21/29) of MSI-M and 77.8% 
(28/36) MSI-U, compared to 46.6% (440/944) of non-MSI 
(P < 0.0001).
BRAF and KRAS mutations were not observed in 
POLE-mutant tumours. In contrast, BRAF mutations 
were observed in 69.0% (20/29) of MSI-M, 11.1% (4/36) 
of MSI-U, and 3.7% (35/944) of non-MSI, whereas KRAS 
mutations were observed in 22.2% (8/36) of MSI-U and 
32.5% (307/944) of non-MSI (P < 0.0001).
Epigenetic features of CRC patients with POLE mutations
To better understand the differences between tumours 
with POLE mutations and the other subtypes, we evalu-
ated the methylation status of discrete regions within the 
promoter of the MGMT and SFRP2 genes.
Concerning MGMT methylation status, lack of meth-
ylation in the minimal promoter (Mp) and enhancer (Eh) 
regions (defined as unmethylated) was observed in 100% 
(4/4) of POLE, 37.9% (11/29) of MSI-M, 75.0% (27/36) of 
MSI-U, and 76.1% (718/944) of non-MSI. Partial meth-
ylation in MGMT (i.e. affecting either MP or Eh) was 
observed in none of the POLE cases, but in 3.5% (1/29) 
of MSI-M, 13.9% (5/36) of MSI-U, and 6.4% (60/944) of 
patients without MSI. Extensive methylation of MGMT 
(i.e. affecting both Mp and Eh) was observed in none of 
the POLE, 58.6% (17/29) of MSI-M, 11.1% (4/36) MSI-U, 
and 17.6% (166/944) non-MSI (P < 0.0001, Fig. 4a, b).
In contrast to MGMT methylation status, lack of meth-
ylation in both region-1 (R1) and region-2 (R2) in SFRP2 
(defined as unmethylated) was not observed in POLE 
G
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G
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G T GG AGT GA
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T C TT GAT GT
Patient‘s ID: 0777, p.P286R (c.857C>G) Patient‘s ID: 0945, P286R, p.P286R (c.857C>G)
Patient‘s ID: 0596, p.V411L (c.1231G>C) Patient‘s ID: 0123, p.S459F (c.1376C>T)
Fig. 2 Detection of POLE proofreading mutations. Among 1,070 CRC tissues analysed, pathogenic somatic POLE proofreading mutations were 
detected in four CRCs (two cases were p.P286R [c.857C > G], one was p.V411L [c.1231G > C], and one was p.S459F [c.1376C > T]) and DNA from their 
corresponding normal mucosa displayed no germline mutations
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or MSI-M, but in 13.9% (5/36) of MSI-U and 15.7% 
(148/944) of non-MSI. Partial methylation in SFRP2 (i.e. 
affecting either R1 or R2) was observed in none of the 
POLE, but in 3.5% (1/29) of MSI-M, 22.2% (8/36) of MSI-
U, and 20.6% (194 of 944) of non-MSI patients. Extensive 
methylation of SFRP2 (i.e. affecting both R1 and R2) was 
observed in all of the POLE, 96.6% (28/29) of MSI-M, 
63.9% (23/36) of MSI-U, and 63.8% (602/944) of non-MSI 
(P = 0.0158, Fig. 4c, d).
Using MLH1, MGMT, and SFRP2 methylation status, 
we calculated the mean methylation score for each sub-
group. When methylation data were analysed using the 
discrete regions in the promoter of the three genes, the 
mean methylation score was significantly higher in MSI-
M, while the mean methylation score in POLE was the 
same as that in MSI-U and non-MSI (MSI-M: 5.2; POLE: 
2.5; MSI-U: 2.2; non-MSI: 2.0, Fig. 5a).
Finally, Table  2 presents detailed information on 
the four POLE-mutant CRC patients. Somatic POLE 
mutations in CRCs are associated with enhanced 
tumour immunogenicity and increased CD8-positive 
lymphocytic infiltration [7, 13, 14, 21]. We examined 
CD8-positive infiltration in the four POLE-mutant 
CRC tissues (Fig.  5b). The number of CD8-positive 
cells per high-power field (HPF, × 400) was increased 
in POLE-mutant patients over 60 years of age at diag-
nosis, who possessed MLH1-AB region methylation 
(Table  2). For reference, we examined the association 
between age at diagnosis, MLH1-AB region methyla-
tion status, and the number of CD8-positive cells per 
HPF (Fig.  5c). The mean age at diagnosis of patients 
with unmethylation in the MLH1-AB region was sig-
nificantly younger than that of patients with methyla-
tion in the MLH1-AB region (65.5  years old [range, 
21–95] vs. 68.7  years old [range, 37–89] years, 
P = 0.001). Although tumour-infiltrating lymphocytes 
were likely to be more common in older POLE-mutant 
patients and/or with methylation in the MLH1-AB 
MLH1-AB MLH1-C 
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Fig. 3 Methylation analysis of the promoter region in the MLH1 gene. a Schematic depiction of two regions (AB and C region) of the MLH1 
promoter for methylation, and results of a panel of representative fluorescent bisulphite PCR following restriction enzyme analysis. AB and 
C region in this study link to A plus B and C plus D region, defined by Deng and colleagues [18], respectivily.  Methylated samples had the new 
fragment cleaved by the restriction enzyme (black triangles). White triangles represent unmethylated alleles. M and U denote methylated and 
unmethylated, respectively. A grey bar denotes an untranslated exon. b The frequencies of MLH1 promoter methylation status among the POLE, 
MSI, and non-MSI groups. Extensive methylation is defined as 5.0% or more methylation on both AB and C regions. Partial methylation is defined as 
5.0% or more methylation on AB region only. c The frequencies of MLH1 promoter methylation status according to MMR protein expression status. 
dMLH1, dMSH2, and dMSH6 denote deficiency of MLH1, MSH2, and MSH6, respectively. pMMR denotes proficiency of all MMR proteins. d The final 
classification of 1,013 CRCs according to POLE mutation, MSI, and MLH1 promoter methylation status. MSI-M denotes MSI tumours with extensive 
MLH1 methylation. MSI-U denotes MSI tumours without extensive MLH1 methylation. The number in each column denotes the number of samples 
classified in each category divided by MLH1 methylation status
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region, the analysed number of patients was too small 
to find associations.
Discussion
In the present study, we report a biologically distinct sub-
set of CRCs with pathogenic somatic POLE mutations, 
especially those with simultaneous epigenetic alterations. 
As previously reported, pathogenic somatic POLE muta-
tions are usually found in the early stages of CRC in the 
right side of the colon and relatively younger patients 
with CRC.
CIN, MSI, and CIMP constitute the three major mech-
anisms of genomic or epigenetic instability in CRC [1, 
2, 5]. Experimental evidence has consistently supported 
the presence of CIMP in a subset of CRCs and correlates 
with the presence of BRAF V600E mutations [1, 22, 23]. 
In terms of CIMP development, it is debatable whether 
BRAF mutations can directly induce CIMP [24, 25]. 
Recently, Tao et  al. [4] reported that the BRAF V600E 
mutation does not directly cause CIMP, and thus, aging-
like acquisition of DNA methylation may favour the 
survival of cells with such mutations in the BRAF gene 
through suppression of senescence and activation of stem 
cell pathways.
Clinically, most sporadic MSI CRCs arise from a 
CIMP background caused by the epigenetic silencing of 
the MLH1 gene, which justifies our reason for selecting 
methylation status of the MLH1 gene at the beginning as 
a critical biomarker for classifying CRCs [1, 26]. CIN and 
CIMP have been proposed to represent two major mech-
anisms of genomic and epigenetic instability in CRC, and 
up to 50% of CRCs may be CIMP positive [1]. Indeed, 
CIMP determinations using CIMP-related markers have 
consistently identified clusters of CRCs with MSI and 
BRAF V600E mutations, but rarely KRAS mutations [27, 
28]. However, when additional methylation loci are inves-
tigated, additional subsets of CRCs have been identified 
with extensive methylation; these tumours are non-MSI 
Table 1 Association between the clinicopathological features of CRC patients stratified by POLE mutation, MSI, and MLH1 methylation 
status
P-values were calculated using the Chi-squared test
*  P-value was calculated between stages I–II and III–IV
Characteristics POLE (n = 4) MSI-M (n = 29) MSI-U (n = 36) non-MSI (n = 944) P value
Age Mean (range) 52.5 (41–63) 76.9 (60–89) 59.5 (24–87) 66.0 (21–95)  < .0001
 > 70 0 (0) 22 (75.9) 7 (19.4) 365 (38.7)  < .0001
55–69 2 (50%) 7 (24.1) 18 (50.0) 441 (46.7)
40–54 2 (50%) 0 (0) 7 (19.4) 118 (12.5)
 < 39 0 (0) 0 (0) 4 (11.1) 20 (2.1)
Gender Female 2 (50%) 19 (65.5%) 13 (36.1%) 389 (41.2%) 0.0593
Male 2 (50%) 10 (34.5%) 23 (63.9%) 555 (58.8%)
Tumour location Right 4 (100%) 27 (93.1%) 13 (36.1%) 282 (29.9%)  < .0001
Left 0 (0) 2 (6.9%) 23 (63.9%) 662 (70.1%)
Histology Well 0 (0) 7 (24.1%) 6 (16.7%) 276 (29.2%)  < .0001
Moderate 3 (75%) 7 (24.1%) 20 (55.6%) 571 (60.5%)
Poor/muc 1 (25%) 15 (51.7%) 10 (27.8%) 97 (10.3%)
UICC stage I 1 (25%) 11 (37.9%) 14 (38.9%) 197 (20.9%) 0.0011
II 3 (75%) 10 (34.5%) 14 (38.9%) 246 (26.1%)  < .0001*
III 0 (0) 6 (20.7%) 4 (11.1%) 297 (31.5%)
IV 0 (0) 2 (6.9%) 4 (11.1%) 204 (21.6%)
RAS mutational status BRAF mutation 0 (0) 20 (69.0%) 4 (11.1%) 35 (3.7%)  < .0001
KRAS mutation 0 (0) 0 (0) 8 (22.2%) 307 (32.5%)
Wild-type 4 (100%) 9 (31.0%) 24 (66.7%) 602 (63.8%)
Methylation score Mean (range) 2 (2) 3.2 (2–4) 1.9 (0–4) 1.9 (0–4)  < .0001
MGMT methylation Extensive 0 (0) 17 (58.6%) 4 (11.1%) 166 (17.6%)  < .0001
Partial 0 (0) 1 (3.5%) 5 (13.9%) 60 (6.4%)
Unmethylation 4 (100%) 11 (37.9%) 27 (75.0%) 718 (76.1%)
SFRP2 methylation Extensive 4 (100%) 28 (96.6%) 23 (63.9%) 602 (63.8%) 0.0158
Partial 0 (0) 1 (3.5%) 8 (22.2%) 194 (20.6%)
Unmethylation 0 (0) 0 (0) 5 (13.9%) 148 (15.7%)
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and are associated with mutations in the KRAS gene [1, 
17, 29]. BRAF and KRAS gene products function in the 
same MAP-kinase signalling pathway, and activating 
mutations in these genes occur mutually exclusive [30, 
31]. Interestingly, before the discovery of BRAF muta-
tions, KRAS mutations have been proposed as a possible 
cause of aberrant methylation. Fibroblasts transformed 
by fos or ras show upregulated DNA methyltransferase 
expression and consequent global hypermethylation [32]. 
Indeed, as previously reported, most non-conventional 
CIMP markers are more likely to gain methylation in 
CRCs with KRAS mutations [26]. Therefore, we hypoth-
esised that CIMP in CRC would result from activat-
ing mutations in either BRAF or KRAS. From this point 
of view, it might be sufficient to summarise the features 
of methylation by using the MLH1, MGMT, and SFRP2 
genes.
In the case of KRAS mutations, promoter methylation 
within the MGMT gene, which encodes a DNA repair 
gene that removes pro-mutagenic  O6-methylguanine 
residues from DNA, is associated with KRAS-mutant 
CRC [17, 26, 33]. Thus, in this study, we examined 
MGMT methylation status to clarify the epigenetic fea-
tures of POLE-mutant CRCs. Interestingly, although 
half of the POLE-mutant CRCs showed partial methyl-
ation in the MLH1 promoter, none of the POLE-mutant 
CRCs displayed any methylation in the discrete pro-
moter regions of the MGMT gene.
In addition to MLH1 and MGMT, we evaluated 
SFRP2 methylation (partial or extensive) because most 
CRCs possess extensive methylation in their promoter 
regions [34–36]. An interesting feature of SFRP2 meth-
ylation is that extensive methylation is rare in adeno-
matous polyps, while it is common in CRCs [35, 36]. 
Additionally, extensive SFRP2 methylation is more fre-
quently observed in CRCs with KRAS mutations than 
in those with BRAF V600E mutations and those with 
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Fig. 4 Methylation analysis of the promoter region in the MGMT and SFRP2 gene. a Schematic depiction of two regions (Mp and Eh region) of 
the MGMT promoter for methylation, and results of a panel of representative fluorescent bisulphite PCR following restriction enzyme analysis. 
Methylated samples had the new fragment cleaved by the restriction enzyme (black triangles). White triangles represent unmethylated alleles. 
M and U denote methylated and unmethylated, respectively. A grey bar denotes an untranslated exon. b The frequencies of MGMT promoter 
methylation status among the POLE, MSI-M, MSI-U, and non-MSI groups. Extensive methylation is defined as 5.0% or more methylation on both Mp 
and Eh regions. Partial methylation is defined as 5.0% or more methylation on either Eh or Mp region. c Schematic depiction of two regions (R1 and 
R2 region) of the SFRP2 promoter for methylation, and results of a panel of representative fluorescent bisulphite PCR following restriction enzyme 
analysis. Methylated samples had the new fragment cleaved by the restriction enzyme (black triangles). White triangles represent unmethylated 
alleles. M and U denote methylated and unmethylated, respectively. A black bar denotes translated exon. d The frequencies of SFRP2 promoter 
methylation status among the POLE, MSI-M, MSI-U, and non-MSI groups. Extensive methylation is defined as 5.0% or more methylation on both 
R1 and R2 region. Partial methylation is defined as 5.0% or more methylation on either R1 or R2 region. The number in each column denotes the 
number of samples classified in each category divided by MGMT or SFRP2 methylation status
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although extensive methylation in MGMT and SFRP2 
has a similar feature in terms of association with CRC 
with KRAS mutations, all POLE-mutant tumours 
demonstrated extensive methylation in SFRP2, but no 
methylation in MGMT.
Temko and colleagues demonstrated that acquisition of 
POLE mutations induces a distinct pattern of mutations 
in cancer driver genes, a substantially increased muta-
tion burden, and an enhanced immune response that is 
detectable even in precancerous lesions [14]. Similar to 
this distinct genetic mutation pattern, although the mean 
methylation score in POLE-mutant tumours was similar 
to that in the MSI-U and non-MSI groups, POLE muta-
tions may also cause a distinct pattern of epigenetic alter-
ations in cancer-associated genes.
POLE-mutant CRCs have been reported to have a 
favourable prognosis, as noted for early-stage dMMR 
tumours [7]. The four POLE-mutant CRC patients in this 
study were diagnosed at stages I to II, and there was no 
recurrence within five years after surgical resection. IHC 
analysis showed that the number of CD8-positive cyto-
toxic tumour-infiltrating lymphocytes in POLE-mutant 
CRCs significantly increased in POLE-wild-type  CRCs, 
especially in mismatch repair protein-proficient CRCs [7, 
14]. We also examined the number of CD8-positive cells 
and compared them to the MLH1-AB region methylation 
status and age at diagnosis. In this study, CD8-positive 
cells were likely to be more common in older POLE-
mutant patients and/or with methylation in the MLH1-
AB region, but the number of analysed POLE-mutant 
patients was too small to reach statistical significance.
Conclusions
Although we analysed over 1,000 CRC samples, CRCs 
with POLE proofreading mutations were found in only 
four tumours. Therefore, this rarity suggests that our 
results should be interpreted with caution. We conclude 
that CRC patients with POLE mutations are rare, such 
mutations are observed in younger individuals, lesions 
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P= .001
Fig. 5 Features of POLE-mutant CRCs. a Mean methylation score in various subgroups of CRCs categorised by POLE mutation, MSI, and MLH1 
promoter methylation status. The mean methylation score in each subset was calculated based on the MLH1, MGMT, and SFRP2 gene (six loci). 
In the red box plot diagrams, the horizontal line within each box represents the median; the limits of each box are the interquartile ranges, the 
whiskers are the maximum and minimum values, and the green horizontal bar within each box depicts the mean value. The numbers under 
the green horizontal bar denote the mean methylation score. The P values above the square panels are statistical differences among any two 
individual groups calculated by the Steel–Dwass test. b Representative immunohistochemical images for the cytotoxic T-cell marker CD8 (brown) 
in POLE-mutant CRC samples. c Association among age at diagnosis, MLH1-AB region methylation status, and the number of CD8-positive ( +) cells 
per HPF in POLE-mutant CRCs. The P value is calculated by the Kruskal–Wallis test. Red circles denote patients with POLE proofreading mutations. 
HPF; high-power field (× 400)
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are often located within the right colon, diagnosis occurs 
at an earlier stage, and distinct epigenetic alterations 
might be associated with CD8 cell infiltration.
Methods
Aim of the study
This study aimed to clarify the incidence of POLE 
proofreading mutations in a large cohort of CRC 
patients in Japan and to evaluate the epigenetic profiles 
of POLE-mutant CRC and elucidate the clinicopatho-
logical features associated with key genetic and epige-
netic alterations in this malignancy.
Study participants and sample collection
A cohort of 1,052 CRC patients underwent surgical resec-
tion between 1998 and 2017 at the Okayama University 
Hospital, Japan. Tumour specimens and correspond-
ing normal mucosa samples were collected according 
to institutional review board (IRB)-approved protocols 
(genome 270 and genome 271 at Okayama University; 
3196–1 and 3239 at Kawasaki Medical School).
Extraction of DNA and bisulphite conversion
Genomic DNA was extracted from fresh-frozen sam-
ples using a QIAamp DNA Mini Kit (Qiagen NV, 
Hilden, Netherlands). The extracted DNA was quanti-
fied using a Qubit 4 fluorometer with a Qubit dsDNA 
BR assay kit (Thermo Fisher Scientific, Cleveland, OH, 
USA). After determining the DNA quality, an EZ DNA 
methylation kit (Zymo Research, USA) was used for 
bisulfite conversion of the normalised samples.
Detection of pathogenic POLE proofreading mutations
Pathogenic POLE hotspot mutations in the proofreading 
domain (exons 9, 13, and 14) were evaluated by Sanger 
sequencing. The primer sequences used are listed in 
Additional file  2: Table  2. PCR products were purified 
using a QIAquick PCR purification kit (Qiagen) and 
directly sequenced using an ABI PRISM® 3100-Avant 
Genetic Analyser (Applied Biosystems) and a SeqStudio 
Genetic Analyser (Thermo Fisher Scientific).
MSI analysis
MSI status was analysed in all CRC tissues using four 
mononucleotide repeat markers (BAT26, NR21, NR27, 
and CAT25), as described previously [12, 16]. When at 
least one or more mononucleotide repeat markers dis-
played MSI, tumours were defined as having an MSI 
phenotype [37]. However, tumours without MSI in the 
four mononucleotide repeat markers were defined as 
having a non-MSI phenotype, as described in our pre-
vious studies [12, 16].
MMR protein and CD8 immunohistochemistry
We employed immunohistochemistry to examine the 
MMR protein expression of MLH1, MSH2, PMS2, and 
MSH6 in primary tumour tissues of CRC specimens 
that showed the MSI phenotype. Staining was per-
formed manually using FFPE specimens. Thin (5  µm) 
sections of representative blocks were deparaffinised 
and dehydrated using gradient solvents. Following 
antigen retrieval in citrate buffer (pH 6.0), endogenous 
peroxidase was blocked with 3%  H2O2. Thereafter, the 
slides were incubated overnight in the presence of 
purified mouse monoclonal antibodies against MLH1 
(clone G168-15, BD Pharmingen, San Diego, CA; dilu-
tion 1:50), MSH2 (clone G219-1129, BD Pharmingen, 
San Diego, CA; dilution 1:200), PMS2 (clone A16-4, BD 
Pharmingen San Diego, CA; dilution 1:200), and MSH6 
protein (clone 44/MSH6, BD Pharmingen San Diego, 
CA; dilution 1:100). Further incubation was performed 
with a secondary antibody and the avidin–biotin–per-
oxidase complex (Vector Laboratories, Burlingame, 
CA, USA), followed by incubation with biotinyl tyra-
mide and streptavidin–peroxidase. Diaminobenzidine 
was used as a chromogen, and haematoxylin was used 
as a nuclear counterstain. Tumour cells were scored 
negative for MMR protein expression only if the epi-
thelial cells within the tumour tissue lacked nuclear 
staining, while the surrounding stromal cells showed 
positive staining. Samples showing proficiency in all 
MMR protein expressions were defined as pMMR, and 
samples showing deficiency in at least one of the four 
MMR proteins were defined as dMMR. When a tumour 
showed neither MLH1 nor PMS2 with staining, the 
tumour was classified as MLH1-deficient (dMLH1); 
when a tumour showed neither MSH2 nor MSH6 with 
staining, the tumour was classified as MSH2-deficient 
(dMSH2); when a tumour showed negative staining 
only for PMS2 but was positive for MLH1, the tumour 
was classified as PMS2-deficient (dPMS2), and when a 
tumour showed negative staining only for MSH6 but 
was positive for MSH2, the tumour was classified as 
MSH6-deficient (dMSH6).
IHC analysis for CD8 was performed in the four POLE-
mutant tumours, as described previously [13]. The num-
ber of CD8-positive cells in the epithelial and stromal 
regions was quantified. The CD8 count per case was eval-
uated in a high-power field (HPF, × 400).
DNA methylation detection within discrete regions 
of the MLH1, MGMT, and SFRP2 gene promoters
In addition to MLH1, we examined the discrete regions 
of MGMT and SFRP2 promoters that affect these expres-
sions or other critical features in tumorigenesis to clarify 
the epigenetic features in tumours with POLE mutations. 
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Like MLH1, the MGMT gene is inactivated as a conse-
quence of extensive methylation in its promoter region 
(dense methylation through minimal promoter [Mp] 
region to enhancer [Eh] region) [17, 26, 38, 39]. Exten-
sive methylation in MGMT is significantly associated 
with MGMT protein downregulation and an increased 
burden of KRAS mutations in CRC patients [17, 33, 38]. 
Consistent with this epigenetic feature, dense methyla-
tion of regions 1 and 2 within the SFRP2 gene promoter 
is a definitive feature of advanced CRCs [4, 34–36].
To quantify the population of methylated alleles of 
the MLH1, MGMT, and SFRP2 promoters in each sam-
ple, a modified combined bisulfite restriction analy-
sis (COBRA) with fluorescence dyes was performed to 
quantitatively measure the methylation density [12, 36, 
38]. The primer sequences and restriction enzymes used 
are listed in Additional file  2:  Table  2. PCR products 
digested with HhaI, RsaI, or Bst UI (New England Bio-
Labs, Ipswich, MA, USA) were loaded simultaneously 
onto a SeqStudio Genetic Analyser (Thermo Fisher Sci-
entific). Signals from individual PCR products were dis-
tinguished by the unique fluorescent PCR signal from 
each target and their fragment length, and the data were 
analysed using GeneMapper software 5 (Applied Biosys-
tems, Foster City, CA, USA). In this study, the percent-
ages of methylated CpG sites (digested by restriction 
enzymes) were calculated by determining the ratios 
between the restriction enzyme-cleaved PCR products 
and the total amount of PCR product in each locus, 
which was defined as the percentage of methylated CpG 
sites at 5.0% or more.
In our cohort of 1,052 CRCs, due to technical chal-
lenges in performing fluorescence bisulfite PCRs for the 
MLH1, MGMT, or SFRP2 genes, two tumours that were 
otherwise characterised as dMLH1 by IHC analysis and 
37 tumours without MSI were excluded from further 
analysis (Fig. 1).
Detection of BRAF and KRAS mutations
Sanger sequencing was performed to confirm mutations 
in KRAS exon 2 and BRAF exon 15 (including codon 
600), as described previously [12, 26]. PCR products 
were purified using a QIAquick PCR purification kit 
(Qiagen) and directly sequenced using an ABI PRISM® 
3100-Avant Genetic Analyser (Applied Biosystems) and 
a SeqStudio Genetic Analyser (Thermo Fisher Scientific).
Statistical analysis
All statistical analyses were performed using JMP Pro 
software (version 14.3; SAS Institute, Inc., Cary, NC, 
USA). Methylation levels in the MLH1, MGMT, and 
SFRP2 promoters were analysed as both continuous and 
categorical variables (methylation level ≥ 5%; unmethyl-
ated: methylation level < 5%).
Categorical variables were compared using the Chi-
squared test. The pair-wise comparisons for each sub-
group were performed using a nonparametric multiple 
comparison method using the Steel–Dwass test. The 
association between age at dignosis and MLH1-AB 
region methylation status was evaluated by the Kruskal-
Wallis test.  All reported P values were two-sided, and 
statistical significance was set at P < 0.05.
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